BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Taiwan

Glac Biotech secures US FDA GRAS for CP-9, cementing Taiwan’s multi-GRAS lead

Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, today announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2...

September 16, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...

September 08, 2025 | News

RemeGen and Santen Form Strategic Alliance on RC28-E for Asia and Greater China

RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...

August 20, 2025 | News

Everest Medicines Secures Full Taiwan Approval for NEFECON® in IgA Nephropathy

Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R...

August 12, 2025 | News

Senhwa Advances CX-5461 into NCI-Sponsored Trial for MYC-Aberrant Lymphoma

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

August 08, 2025 | News

Energenesis Completes Phase I Trial of ENERGI-F705PD, a Novel Oral Therapy for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pha...

August 04, 2025 | News

Senhwa Biosciences’ CX-5461 Selected by U.S. National Cancer Institute for Major Oncology Research Programme

Senhwa Biosciences, Inc., a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, ...

July 17, 2025 | News

DIVA Marks 30 Years with Industry-First Surgical Displays and OLED Breakthroughs in Medical Imaging

DIVA, a professional medical display manufacturer with 30 years of experience, announces three major product developments that reinforce its commitment to ...

July 17, 2025 | News

Fujitsu and Acer Medical to Launch AI-Powered Gait Analysis for Early Dementia and Parkinson’s Detection in Taiwan

Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to dev...

July 16, 2025 | News

Taiwan’s Senhwa Biosciences’ CX-5461 Selected by U.S. National Cancer Institute for Major Oncology Research Programme

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

July 16, 2025 | News

Inocras Partners with Chi Mei Medical Center and Trivator to Advance Precision Oncology in Taiwan

Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, today announced the signing of a Memorandum of Understanding (MOU) with ...

July 09, 2025 | News

Taiwan Steps Into the Global Spotlight With a New Cancer Therapy

Traditional therapies often fall short in targeting these aggressive cancers with precision or safety. Can SOB100 improve drug delivery without the usual s...

July 02, 2025 | Report

HanchorBio Licenses Novel CD47 Fusion Protein HCB101 to Henlius in $200 Million+ Regional Deal

HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, annou...

July 02, 2025 | News

Stay Connected